Literature DB >> 22771712

Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West.

Quirino Lai1, Alfonso W Avolio, Jan Lerut, Gurusharan Singh, See Ching Chan, Pasquale B Berloco, Giuseppe Tisone, Salvatore Agnes, Kenneth S Chok, William Sharr, Massimo Rossi, Tommaso M Manzia, Chung Mau Lo.   

Abstract

BACKGROUND & AIMS: Greater tumor aggressiveness and different management modalities of hepatocellular cancer (HCC) before liver transplantation (LT) may explain the higher recurrence rates reported in Asia. This study investigates the prognostic factors for HCC recurrence in a Western and an Eastern HCC patient cohort in order to analyze the respective roles of tumor- and management-related factors on the incidence of post-LT HCC recurrence.
METHODS: Data of 273 HCC patients, transplanted during the period January 1999-March 2009, were obtained from the Rome Inter-University Liver Transplant Consortium (n=157) and Hong Kong University (n=116) databases. Median follow-up was 4.3 years (range: 0.2-12). Recurrence rate and multivariate logistic regression analysis was performed on the entire population and on Milan criteria-in (MC-in) patients.
RESULTS: Multivariate analysis on the entire population identified four independent risk factors for post-LT HCC recurrence: microvascular invasion (odds ratio, OR=4.88; p=0.001), poor tumor grading (OR=6.86; p=0.002), diameter of the largest tumor (OR=4.72; p=0.05), and previous liver resection (LR) (OR=3.34; p=0.04). After removal of LR, only tumor-related variables were independent risk factors for recurrence. When only MC-in patients were analyzed, no difference was observed between the two cohorts in terms of recurrence rate after LR patient removal.
CONCLUSIONS: LR followed by salvage "for HCC recurrence" LT represents the main reason for a higher HCC recurrence rate in the Hong Kong patients, but not LR followed by salvage "for liver failure" LT in the Roman group. This approach towards HCC before LT may not be universally applicable. The precise patient background must be taken into account in order to identify the best pre-LT strategy.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22771712     DOI: 10.1016/j.jhep.2012.06.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

Review 1.  Liver transplantation in 2012: Transplantation for liver cancer--more with better results.

Authors:  Chung-Mau Lo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

2.  Comparison of laparoscopic hepatectomy, percutaneous radiofrequency ablation and open hepatectomy in the treatment of small hepatocellular carcinoma.

Authors:  Chong Lai; Ren-an Jin; Xiao Liang; Xiu-jun Cai
Journal:  J Zhejiang Univ Sci B       Date:  2016-03       Impact factor: 3.066

Review 3.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

4.  Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.

Authors:  Quirino Lai; Milton Inostroza; Juan M Rico Juri; Pierre Goffette; Jan Lerut
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

Review 5.  The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution.

Authors:  Quirino Lai; Samuele Iesari; Fabio Melandro; Gianluca Mennini; Massimo Rossi; Jan Lerut
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-16

Review 6.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

7.  Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

Authors:  Robert J Wong; James Wantuck; Antonia Valenzuela; Aijaz Ahmed; Clark Bonham; Amy Gallo; Marc L Melcher; Glen Lutchman; Waldo Concepcion; Carlos Esquivel; Gabriel Garcia; Tami Daugherty; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 8.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

Review 9.  Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.

Authors:  Xiang-Qian Gu; Wei-Ping Zheng; Da-Hong Teng; Ji-San Sun; Hong Zheng
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

10.  Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Dawei Chen; Shuanghai Liu; Sheng Chen; Zhaowen Wang; Zehua Wu; Kai Ma; Junwei Fan; Zhihai Peng
Journal:  Int J Clin Oncol       Date:  2016-07-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.